Adult patients with relapsed or refractory MCL after at least two prior systemic therapies, including a BTK inhibitor.
Adult patients with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
These indications are approved under accelerated approval based on response rate.
- Side effects of Pirtobrutinib Pirtobrutinib is a kinase inhibitor. Like most powerful drugs, the use of Pirtobrutinib is accompanied by a series of potential side effects. This article will explore the side effects, mitigation measures, and daily precautions of Pirtobrutinib in depth to help patients better manage discomfort during treatment.
Jul 04, 2025, 15:01 GMT+08:00
- Precautions for Pirtobrutinib As an oral targeted drug, the standard dose of Pirtobrutinib is 200mg once daily, but special attention should be paid to its safety issues such as liver toxicity and infection risk. Patients should fully understand the precautions of Pirtobrutinib.
Jul 04, 2025, 14:56 GMT+08:00
Indicated in combination with fulvestrant for adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer harboring one or more alterations in PIK3CA, AKT1, or PTEN, as detected by an FDA-approved test, following disease progression on or after endocrine therapy.
- Instructions for use and indications of Indian Capivasertib Capivasertib(Truqap) is a targeted therapy for patients with specific breast lesions and should be used strictly in accordance with the doctor's instructions. Correct use of the drug can improve efficacy and reduce the risk of adverse reactions. The following content will explain in detail its specific usage and precautions.
Jul 04, 2025, 13:57 GMT+08:00
- A brief introduction to Capivasertib Capivasertib(Truqap) is a new type of targeted therapy for patients with specific types of advanced or metastatic breast lesions. The drug works by inhibiting the PI3K/AKT signaling pathway, providing a new treatment option for patients with hormone receptor (HR) positive, HER2 negative and PIK3CA/AKT1/PTEN gene mutations.
Jul 04, 2025, 13:53 GMT+08:00
PIQRAY, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following disease progression on or after endocrine-based regimen.
- Precautions for the Administration of Alpelisib (Piqray) Alpelisib (Piqray) is a phosphatidylinositol-3-kinase (PI3K) inhibitor administered orally, and strict adherence to dosage adjustments and adverse reaction monitoring is required.
Sep 04, 2025, 16:36 GMT+08:00
- What are the precautions for Alpelisib (PIQRAY)? Alpelisib (PIQRAY) is a targeted therapy for patients with breast-related diseases with specific gene mutations. Its unique mechanism of action brings new hope for treatment for patients with breast-related diseases.
Jul 07, 2025, 11:31 GMT+08:00
CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who have been identified as CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) via an FDA-cleared test. It is not recommended for ultra-rapid metabolizers (URMs) or indeterminate metabolizers.
- Precautions for the use of Elglustat Elglustat is a targeted therapeutic drug for Gaucher disease. During its use, relevant precautions must be strictly followed to help patients take the drug and maximize the therapeutic effect. This article will discuss in detail the precautions, specifications, properties, and dosage of Elglustat in order to provide comprehensive guidance for patients.
Jul 04, 2025, 16:25 GMT+08:00
- Side effects of Elglustat Although Elglustat is effective in improving patient symptoms, some side effects may occur during use. This article will introduce the side effects, relief measures and daily precautions of Elglustat in detail to help patients better manage the treatment process.
Jul 04, 2025, 16:22 GMT+08:00
VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
- Precautions for Dacomitinib It is of great importance for both patients and doctors to understand the precautions before using dacomitinib (Vizimpro). Dacomitinib is an oral targeted therapeutic drug, commonly used in the treatment of non-small cell lung cancer (NSCLC) with EGFR gene mutations. To ensure the safety and effectiveness of the treatment, patients should understand and comply with some important precautions.
Sep 08, 2025, 17:01 GMT+08:00
- Dacomitinib: Clinical Uses, Recommended Dosage, Potential Side Effects Dacomitinib is an oral tyrosine kinase inhibitor primarily used as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) harboring specific EGFR gene mutations. EGFR, a cell surface receptor, is involved in processes such as cell growth, differentiation, and survival. In some NSCLC patients, specific mutations in the EGFR gene exist (e.g., exon 19 deletion or exon 21 L858R substitution mutation). These mutations lead to abnormal activation of the EGFR signaling pathway, which in turn promotes the growth and spread of tumor cells. Currently, dacomitinib has been launched in China. This article provides a detailed description of its indications, dosage and administration, side effects, contraindications, clinical efficacy, and other aspects.
Sep 08, 2025, 16:56 GMT+08:00
Adult patients with relapsed or refractory MCL after at least two prior systemic therapies, including a BTK inhibitor.
Adult patients with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
These indications are approved under accelerated approval based on response rate.
Indicated in combination with fulvestrant for adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer harboring one or more alterations in PIK3CA, AKT1, or PTEN, as detected by an FDA-approved test, following disease progression on or after endocrine therapy.
PIQRAY, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following disease progression on or after endocrine-based regimen.
CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who have been identified as CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) via an FDA-cleared test. It is not recommended for ultra-rapid metabolizers (URMs) or indeterminate metabolizers.
VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
Lapatinib in combination with capecitabine is indicated for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapies including anthracyclines, taxanes, and trastuzumab. (Usage restriction: Before initiating treatment with lapatinib combined with capecitabine, patients must have experienced disease progression during trastuzumab treatment.)
Lapatinib in combination with letrozole is indicated for the treatment of postmenopausal women with hormone receptor-positive, metastatic breast cancer that overexpresses the HER2 receptor. The combination of lapatinib with an aromatase inhibitor (letrozole in this case) has not been compared with trastuzumab-containing chemotherapy regimens for the treatment of metastatic breast cancer.
- How Effective is Cuvrior (Trientine) in Treatment? Cuvrior (trientine) is a copper chelating agent, with trientine tetrahydrochloride as its main active ingredient. It is indicated for the treatment of Wilson's disease in adult patients who have achieved copper depletion and are tolerant to penicillamine.
503
2025-09-10 11:03:08 - How Effective is ExtraSuperTadarise? ExtraSuperTadarise is a combined medication primarily used for the treatment of male erectile dysfunction (ED) and premature ejaculation (PE). Its unique formulation integrates two active ingredients, which not only help improve erectile function but also prolong the duration of sexual activity. 501
2025-09-09 17:27:50
- Precautions for Administration of ExtraSuperTadarise ExtraSuperTadarise is a compound preparation mainly containing Tadalafil and Dapoxetine. It is used for the treatment of male erectile dysfunction (ED) and premature ejaculation (PE). Due to the particularity of its compound ingredients, strict compliance with medication standards is required in clinical use. 501
2025-09-09 17:25:05
- What are the side effects of ExtraSuperTadarise? ExtraSuperTadarise is a compound medication used for the treatment of male erectile dysfunction (ED) and premature ejaculation (PE). Its main active ingredients are Tadalafil and Dapoxetine. Although it has good therapeutic effects, side effects may occur during use. It is necessary to understand the relevant symptoms, relief methods, and follow the daily precautions. 501
2025-09-09 17:23:01
- Precautions for Cuvrior Administration Cuvrior is a copper chelating agent, with the main active ingredient being trientine tetrahydrochloride. It is indicated for the treatment of adult patients with Wilson's disease who have achieved cupruresis (copper depletion) and are intolerant to penicillamine. As a specialized metal chelating agent, its clinical use must strictly adhere to standard protocols. 501
2025-09-09 16:55:08
- What Are the Side Effects of Valcyte? Valcyte is an anti-cytomegalovirus (CMV) drug, with valganciclovir as its main active ingredient. It is used for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). As a prodrug, it is converted into ganciclovir in the body to exert its therapeutic effect. During medication, attention should be paid to risks such as hematological toxicity and reproductive toxicity, and methods for managing side effects as well as daily precautions should be well mastered. 502
2025-09-09 16:46:05
- How Effective is Valcyte? Valcyte is an antiviral medication whose main active ingredient is valganciclovir hydrochloride. It is used for the treatment of cytomegalovirus (CMV) infections. 502
2025-09-09 16:39:16
- Precautions for the use of valcyte Valcyte (active ingredient: valganciclovir hydrochloride) is an antiviral medication indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). Due to its unique pharmacological properties and potential for severe adverse reactions, its clinical use must strictly adhere to medication guidelines. 501
2025-09-09 16:35:21
- How to Use Valcyte Valcyte (generic name: Valganciclovir Hydrochloride Tablets) is an antiviral medication, with valganciclovir hydrochloride as its main active ingredient. It is indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). As a prodrug of ganciclovir, Valcyte is rapidly converted into ganciclovir in the body after oral administration to exert its therapeutic effect. 501
2025-09-09 16:22:39
- Indications of Valcyte Valcyte (valganciclovir hydrochloride) is an antiviral prodrug, whose main component is valganciclovir hydrochloride. After oral administration, it is rapidly converted into ganciclovir in the body. As a CMV-specific inhibitor, it effectively inhibits the replication of human cytomegalovirus (CMV) by competitively blocking viral DNA polymerase. 501
2025-09-09 16:17:54
